CompletedNCT02498392
JNJ-42165279 for Major Depression With Anxiety Symptoms
About this title
Read the official source — NCT02498392Researchers compared JNJ-42165279 and placebo to find out how the approaches affected depression symptoms in people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
Researchers compared JNJ-42165279 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Costa Mesa and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 7, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 161
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Moldova, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02498392
- Official title
Show the full official title
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedCosta Mesa, United States · Oceanside, United States · Miami, United States
30 more locations
- Natick, United States
- Cedarhurst, United States
- Raleigh, United States
- Allentown, United States
- Salt Lake City, United States
- Chisinau, Moldova
- Orenburg, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Yekaterinburg, Russia
- Alicante, Spain
- Barcelona, Spain
- Bilbao, Spain
- Sant Boi de Llobregat, Spain
- Zamora, Spain
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Smila, Ukraine
- Uzhhorod, Ukraine
- Barnsley, United Kingdom
- Blackpool, United Kingdom
- Liverpool, United Kingdom
- Manchester, United Kingdom
- South Staffordshire, United Kingdom
- Stourton, United Kingdom
- Russia
Questions about this study
What did researchers investigate?
Researchers compared JNJ-42165279 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including JNJ-42165279.
Who was this study for?
Listed age limits: 18 years to 64 years.
Want to explore more studies?
Explore studiesRelated studies
A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet...
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di...